1/31/2013

The FDA approved antisense drug Kynamro to treat homozygous familial hypercholesterolemia, a rare, inherited disorder. The technology on which the drug is based was initially developed by Gilead Sciences, which sold its patents to Isis Pharmaceuticals. Sarepta Therapeutics and Prosensa are developing gene-silencing drugs to treat muscular dystrophy.

Related Summaries